Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

Investigational new drug

PharmaDrug (BUZZ.C) passed their potential cancer fighter, cepharanthine02HC1, the active ingredient in their oral drug PD-001, through preclinicals today.   The results of the test are good. It’s proven…
Pharmadrug’s (BUZZ.C) subsidiary Sairiyo Therapeutics received their orphan drug designation (ODD) for dimethyltryptamine (DMT) from the United States Food and Drug Administration (FDA) for the prevention of ischemia-reperfusion injury…
“Psilocybin offers a potential solution to manage moderate to severe cases of TBI,” stated RVV, “Psilocybin has the potential with its neuroreparative effect to improve loss of cognitive function…
Cybin’s (CYBN.NE) subsidiary Adelia Therapeutics completed earnout milestones originally set in a contribution agreement for the period of January 1, 2021, following Cybin’s acquisition of Adelia. There are a…
Investor focus is currently bifurcated between a potential FDA bucillamine approval, and RVV’s ambitions and partnerships in the shroom space….
The collaboration will “accelerate the development of psilocybin in the treatment of cancer and the discovery of novel uses of undisclosed psychedelic compounds”….
On November 11, 2020 Revive Therapeutics (RVV.C) Revive Therapeutics updated shareholders on its oral thin-film delivery system with psilocybin being developed “under a research partnership agreement with Reed Research…
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focused on developing coronavirus solutions….
Given the grim human and financial data, it’s no surprise that biotech companies and their shareholders are focussed on developing coronavirus solutions….
Revive has a partnership agreement with the Reed Research Group out of the University of Wisconsin-Madison to evaluate novel formulations of psilocybin….